<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7029664/results/search/disease/results.xml">
  <result pre=": italic;} Clin Exp PediatrClin Exp PediatrCEPClinical and Experimental Pediatrics2713-4148Korean" exact="Pediatric" post="Society pmcid: 7029664 pmid: 32024333 doi: 10.3345/kjp.2019.01116kjp-2019-01116 : Editorial:"/>
  <result pre="doi: 10.3345/kjp.2019.01116kjp-2019-01116 : Editorial: Gastroenterology Strategies for treating and managing" exact="chronic hepatitis" post="C in children in the direct-acting antiviral era HongSuk-JinMD1http://orcid.org/0000-0001-9899-9120ChoeByung-HoMDPhD2[1],"/>
  <result pre="10.3345/kjp.2019.01116kjp-2019-01116 : Editorial: Gastroenterology Strategies for treating and managing chronic" exact="hepatitis" post="C in children in the direct-acting antiviral era HongSuk-JinMD1http://orcid.org/0000-0001-9899-9120ChoeByung-HoMDPhD2[1],"/>
  <result pre="in any medium, provided the original work is properly cited." exact="Hepatitis" post="C virus (HCV) transmission occurs by the parenteral route"/>
  <result pre="not spread by casual contact. The main route of HCV" exact="infection" post="in children is vertical transmission by infected mothers [1]."/>
  <result pre="no protective vaccine against HCV. The framework for treating HCV" exact="infection" post="is changing rapidly. New short-course oral direct-acting antiviral (DAA)"/>
  <result pre="have approved DAA regimens for the treatment of adults with" exact="chronic" post="HCV infection. Both agencies approved DAA therapy (sofosbuvir or"/>
  <result pre="any genotype was approved for Korean children (aged ≥12 years)." exact="Pediatric" post="studies showed that DAA combination therapy is far superior"/>
  <result pre="trials [3]. Compared to studies of DAA in children with" exact="chronic" post="HCV infection, the therapeutic efficacy of pegylated interferon (PegIFN)"/>
  <result pre="et al. [5] investigated thyroid dysfunction in children with HCV" exact="infection" post="receiving PegIFN plus ribavirin and showed that 28% of"/>
  <result pre="IFN use [6]. The types of thyroid dysfunction were subclinical" exact="hypothyroidism" post="(50.7%), and so on such as hypo-, hyper-, and"/>
  <result pre="(50.7%), and so on such as hypo-, hyper-, and subclinical" exact="hyperthyroidism" post="and thyroiditis [7]. The approval of DAA for use"/>
  <result pre="so on such as hypo-, hyper-, and subclinical hyperthyroidism and" exact="thyroiditis" post="[7]. The approval of DAA for use in children"/>
  <result pre="Although PegIFN plus ribavirin is approved for children with HCV" exact="infection" post="(age ≥3 years), IFN treatment is no longer recommended"/>
  <result pre="regimens are approved for children (aged &amp;lt;12 years) because HCV-related" exact="liver disease" post="occurs infrequently in children [1,8]. In the near future,"/>
  <result pre="are approved for children (aged &amp;lt;12 years) because HCV-related liver" exact="disease" post="occurs infrequently in children [1,8]. In the near future,"/>
  <result pre="for all HCV-infected children (≥3 years of age) independent of" exact="disease" post="severity [1,9]. According to a recent guideline for HCV"/>
  <result pre="OrganizationGuidelines for the care and treatment of persons diagnosed with" exact="chronic hepatitis" post="C virus infection [Internet]Geneva (Switzerland)World Health Organization2018[cited 2019 Sep"/>
  <result pre="for the care and treatment of persons diagnosed with chronic" exact="hepatitis" post="C virus infection [Internet]Geneva (Switzerland)World Health Organization2018[cited 2019 Sep"/>
  <result pre="care and treatment of persons diagnosed with chronic hepatitis C" exact="virus infection" post="[Internet]Geneva (Switzerland)World Health Organization2018[cited 2019 Sep 15]. Available from:"/>
  <result pre="and treatment of persons diagnosed with chronic hepatitis C virus" exact="infection" post="[Internet]Geneva (Switzerland)World Health Organization2018[cited 2019 Sep 15]. Available from:"/>
  <result pre="Available from: https://www.who.int/hepatitis/publications/hepatitisc-guidelines-2018 2KimBKJangESKimJHParkSYAhnSVKimHJet al.Current status of and strategies for" exact="hepatitis" post="C control in South KoreaClin Mol Hepatol201723212828942625 3IndolfiGSerrantiDRestiMDirect-acting antivirals"/>
  <result pre="KoreaClin Mol Hepatol201723212828942625 3IndolfiGSerrantiDRestiMDirect-acting antivirals for children and adolescents with" exact="chronic hepatitis" post="CLancet Child Adolesc Health2018229830430169301 4WirthSRibes-KoninckxCCalzadoMABortolottiFZancanLJaraPet al.High sustained virologic response"/>
  <result pre="Mol Hepatol201723212828942625 3IndolfiGSerrantiDRestiMDirect-acting antivirals for children and adolescents with chronic" exact="hepatitis" post="CLancet Child Adolesc Health2018229830430169301 4WirthSRibes-KoninckxCCalzadoMABortolottiFZancanLJaraPet al.High sustained virologic response"/>
  <result pre="Health2018229830430169301 4WirthSRibes-KoninckxCCalzadoMABortolottiFZancanLJaraPet al.High sustained virologic response rates in children with" exact="chronic hepatitis" post="C receiving peginterferon alfa-2b plus ribavirinJ Hepatol201052501720189674 5RashedYKKhalafFAKotbSEThyroid disturbances"/>
  <result pre="4WirthSRibes-KoninckxCCalzadoMABortolottiFZancanLJaraPet al.High sustained virologic response rates in children with chronic" exact="hepatitis" post="C receiving peginterferon alfa-2b plus ribavirinJ Hepatol201052501720189674 5RashedYKKhalafFAKotbSEThyroid disturbances"/>
  <result pre="children treated with combined Pegylated Interferon alpha and Ribavirin for" exact="chronic hepatitis" post="CClin Exp Pediatr20206352532024338 6MandacJCChaudhrySShermanKETomerYThe clinical and physiological spectrum of"/>
  <result pre="treated with combined Pegylated Interferon alpha and Ribavirin for chronic" exact="hepatitis" post="CClin Exp Pediatr20206352532024338 6MandacJCChaudhrySShermanKETomerYThe clinical and physiological spectrum of"/>
  <result pre="dysfunction during peginterferon α and ribavirin treatment in patients with" exact="chronic hepatitis" post="CKorean J Intern Med20153079280026552454 8collab: European Association for the"/>
  <result pre="during peginterferon α and ribavirin treatment in patients with chronic" exact="hepatitis" post="CKorean J Intern Med20153079280026552454 8collab: European Association for the"/>
  <result pre="the Study of the Liver. EASL Recommendations on Treatment of" exact="Hepatitis" post="C 2018J Hepatol20186946151129650333 9collab: The American Association for the"/>
  <result pre="Recommendations on Treatment of Hepatitis C 2018J Hepatol20186946151129650333 9collab: The" exact="American" post="Association for the Study of Liver Diseases, the Infectious"/>
  <result pre="2018J Hepatol20186946151129650333 9collab: The American Association for the Study of" exact="Liver Diseases," post="the Infectious Diseases Society of AmericaHCV guidance: recommendations for"/>
  <result pre="The American Association for the Study of Liver Diseases, the" exact="Infectious" post="Diseases Society of AmericaHCV guidance: recommendations for testing, managing,"/>
  <result pre="American Association for the Study of Liver Diseases, the Infectious" exact="Diseases" post="Society of AmericaHCV guidance: recommendations for testing, managing, and"/>
  <result pre="Society of AmericaHCV guidance: recommendations for testing, managing, and treating" exact="hepatitis" post="C [Internet]AASLD, IDSA; [cited 2019 Sep 14]. Available from:"/>
  <result pre="years Adverse reactions Minor PegIFN: flu-like symptoms, neuropsychiatric symptoms, leukopenia," exact="thyroid disease" post="Ribavirin: hematological complication such as hemolytic anemia Contraindication None"/>
  <result pre="Adverse reactions Minor PegIFN: flu-like symptoms, neuropsychiatric symptoms, leukopenia, thyroid" exact="disease" post="Ribavirin: hematological complication such as hemolytic anemia Contraindication None"/>
  <result pre="neuropsychiatric symptoms, leukopenia, thyroid disease Ribavirin: hematological complication such as" exact="hemolytic anemia" post="Contraindication None PegIFN: hypersensitivity reactions to interferon, hepatic decompensation"/>
  <result pre="symptoms, leukopenia, thyroid disease Ribavirin: hematological complication such as hemolytic" exact="anemia" post="Contraindication None PegIFN: hypersensitivity reactions to interferon, hepatic decompensation"/>
  <result pre="Ribavirin: hematological complication such as hemolytic anemia Contraindication None PegIFN:" exact="hypersensitivity" post="reactions to interferon, hepatic decompensation (Child–Pugh class B, C)"/>
 </snippets>
</snippetsTree>
